Newron Pharmaceuticals Sp A
Biotechnology, Bresso, North Carolina, 27604, United States, 11-50 Employees
Phone Number: 39 02 61* 34**
Who is NEWRON PHARMACEUTICALS SPA
Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering...
Read More
-
Headquarters: Bresso, North Carolina, 27604, United States
-
Date Founded: 1999
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from NEWRON PHARMACEUTICALS SPA
Newron Pharmaceuticals SpA Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Newron Pharmaceuticals SpA
Answer: Newron Pharmaceuticals SpA's headquarters are located at Bresso, North Carolina, 27604, United States
Answer: Newron Pharmaceuticals SpA's phone number is 39 02 61* 34**
Answer: Newron Pharmaceuticals SpA's official website is https://newron.com
Answer: Newron Pharmaceuticals SpA's revenue is $5 Million to $10 Million
Answer: Newron Pharmaceuticals SpA's SIC: 8731
Answer: Newron Pharmaceuticals SpA's NAICS: 541715
Answer: Newron Pharmaceuticals SpA has 11-50 employees
Answer: Newron Pharmaceuticals SpA is in Biotechnology
Answer: Newron Pharmaceuticals SpA contact info: Phone number: 39 02 61* 34** Website: https://newron.com
Answer: Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago (safinamide) has received marketing authorization for the treatment of Parkinsons disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newrons Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the US. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago for Parkinsons disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Dusseldorf Stock Exchange and on XETRA, trading symbol NP5.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month